Treatments administered at CAR T-cell progression/relapse
| Treatment . | n = 154 . |
|---|---|
| IMID lenalidomide∗ | 59 (38.3) |
| Bispecific antibodies anti-CD20-CD3 | 11 (7.1) |
| Target therapy† | 33 (21.4) |
| Nivolumab | 11 (7.1) |
| Pembrolizumab | 4 (2.6) |
| Ibrutinib | 3 (1.9) |
| Ibrutinib + lenalidomide + rituximab | 2 (1.3) |
| Ibrutinib + corticosteroids | 2 (1.3) |
| Ibrutinib + lenalidomide | 1 (0.6) |
| Nivolumab + brentuximab vedotin | 1 (0.6) |
| Pembrolizumab + lenalidomide | 1 (0.6) |
| Lenalidomide + polatuzumab vedotin | 1 (0.6) |
| Busulfan + fludarabine + nivolumab + thiotepa | 1 (0.6) |
| Clinical trial LYM 1002‡ | 1 (0.6) |
| MALT-1 inhibitor | 1 (0.6) |
| Anti-CD20 monoclonal antibody | 3 (1.9) |
| Other monoclonal antibody (anti-CD38, anti-CD30, anti-CD79b) | 1 (0.6) |
| Radiotherapy | 17 (11.0) |
| Immunochemotherapy | 31 (20.1) |
| Palliative corticosteroids | 1 (0.6) |
| Treatment . | n = 154 . |
|---|---|
| IMID lenalidomide∗ | 59 (38.3) |
| Bispecific antibodies anti-CD20-CD3 | 11 (7.1) |
| Target therapy† | 33 (21.4) |
| Nivolumab | 11 (7.1) |
| Pembrolizumab | 4 (2.6) |
| Ibrutinib | 3 (1.9) |
| Ibrutinib + lenalidomide + rituximab | 2 (1.3) |
| Ibrutinib + corticosteroids | 2 (1.3) |
| Ibrutinib + lenalidomide | 1 (0.6) |
| Nivolumab + brentuximab vedotin | 1 (0.6) |
| Pembrolizumab + lenalidomide | 1 (0.6) |
| Lenalidomide + polatuzumab vedotin | 1 (0.6) |
| Busulfan + fludarabine + nivolumab + thiotepa | 1 (0.6) |
| Clinical trial LYM 1002‡ | 1 (0.6) |
| MALT-1 inhibitor | 1 (0.6) |
| Anti-CD20 monoclonal antibody | 3 (1.9) |
| Other monoclonal antibody (anti-CD38, anti-CD30, anti-CD79b) | 1 (0.6) |
| Radiotherapy | 17 (11.0) |
| Immunochemotherapy | 31 (20.1) |
| Palliative corticosteroids | 1 (0.6) |
Values are n (%). A total of 7% of patients (n = 17) did not receive any treatment because their disease was too advanced.
IMID, immunomodulatory drug; MALT-1, mucosa-associated lymphoid tissue lymphoma translocation protein 1.
Ten patients received lenalidomide alone; 49 received lenalidomide in combination, including 46 with rituximab.
Among the 33 patients who received targeted therapies, 24 received monotherapy, and 9 received combination therapy (all with different drugs).
MALT-1 inhibitor + ibrutinib.